Phathom Pharmaceuticals

Going beyond to advance treatments for patients with acid-related disorders

Founded 2018

United States 395 employees Post-IPO Equity Total: $530.30M Biotechnology, Pharmaceutical

Phathom Pharmaceuticals is a biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. Established in 2018 and headquartered in the United States, the company is listed on Nasdaq under the ticker symbol PHAT. With the slogan "Going beyond to advance treatments for patients with acid-related disorders," Phathom Pharmaceuticals is focused on addressing unmet needs for patients and improving their quality of life in the Biotechnology and Pharmaceutical industries. The company prides itself on a team of highly driven pharmaceutical professionals who are passionate about their mission. They prioritize inclusion and belonging, ensuring all voices are heard, holding themselves accountable to be equitable and just, and authentically supporting the people and communities impacted by their work. Phathom Pharmaceuticals recently secured a $150.30M Post-IPO Equity investment on 23 May 2023, reflecting investor confidence in the company's vision and potential for growth. As the company continues to expand, it is actively seeking self-motivated, creative problem solvers who are eager to contribute to its fast-paced start-up environment.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$150.30M	-		23 May 2023
Post IPO Debt	$40.00M	3	Hercules Capital, Novaquest Capital Management +1	01 Nov 2022
Post IPO Debt	$200.00M	1	Hercules Capital	20 Sep 2021
Debt Financing	$50.00M	1	Silicon Valley Bank	15 May 2019
Private Equity Round	$90.00M	5	Abingworth, Frazier Healthcare Partners +3	15 May 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$150.30M

23 May 2023

Post IPO Debt

$40.00M

Hercules Capital, Novaquest Capital Management +1

01 Nov 2022

Post IPO Debt

$200.00M

Hercules Capital

20 Sep 2021

Debt Financing

$50.00M

Silicon Valley Bank

15 May 2019

Private Equity Round

$90.00M

Abingworth, Frazier Healthcare Partners +3

15 May 2019

FAQ About Phathom Pharmaceuticals

Going beyond to advance treatments for patients with acid-related disorders

Phathom Pharmaceuticals was founded in 2018.

Phathom Pharmaceuticals is headquartered in United States.

Phathom Pharmaceuticals operates in Biotechnology and Pharmaceutical. Its work centres on Biopharmaceuticals, Gastrointestinal disorders, Clinical drug development and Innovation in healthcare.

Phathom Pharmaceuticals has approximately 395 employees.

Phathom Pharmaceuticals has completed 5 funding rounds, raising a total of $530.30M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Phathom Pharmaceuticals include Atlantic Healthcare, NeuroDerm, A Mitsubishi Tanabe Pharma Group Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Phathom Pharmaceuticals and Atlantic Healthcare are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Phathom Pharmaceuticals

Funding Rounds & Investors (5)

Phathom Pharmaceuticals Alternatives & Competitors

FAQ About Phathom Pharmaceuticals